Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1459977

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, what progress has been made on the assessment of Evusheld for treating immunocompromised patients.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158928
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.</p><p>The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.</p> answering member constituency Erewash answering member printed Maggie Throup grouped question UIN 158929 159058 question first answered 28/04/2022 08:34:34 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459978

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, when patients in the UK will have access to Evusheld as a preventative treatment for covid-19.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158929
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.</p><p>The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.</p> answering member constituency Erewash answering member printed Maggie Throup grouped question UIN 158928 159058 question first answered 28/04/2022 08:34:34 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459979

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what timeframe the UK Health Security Agency are working to in order to assess the effectiveness of Evusheld against the Omicron variant of covid-19.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158930
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 28/04/2022 11:17:32 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459980

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of immunocompromised individuals who have (a) been hospitalised and (b) died as a result of covid-19 since the MHRA authorised Evusheld for use in the UK.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158931
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 28/04/2022 08:55:40 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459981

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many immunocompromised people remain shielding against covid-19; and what assessment he has made of the impact of that shielding on people's social interactions, mental health and economic activity.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158932
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>The information requested is not held centrally as the shielding programme ended in September 2021. The Office for National Statistics’ ‘Coronavirus and clinically extremely vulnerable people in England’ survey includes information on the behaviours of clinically extremely vulnerable people and their health and wellbeing, which is available at the following link:</p><p><a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronavirusandclinicallyextremelyvulnerablepeopleinengland" target="_blank">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronavirusandclinicallyextremelyvulnerablepeopleinengland</a></p> answering member constituency Erewash answering member printed Maggie Throup question first answered 28/04/2022 10:42:26 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459983

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has assessed the number of immunocompromised patients who have received antiviral treatment in response to covid-19 and who have subsequently (a) been hospitalised and (b) died as a result of covid-19.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158933
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 28/04/2022 08:56:19 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459984

registered interest
date	25/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of immunocompromised patients received antiviral treatments within five days of the first symptoms, as recommended by the MHRA.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158934
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 28/04/2022 11:18:44 answering member 4447 label Biography information for Maggie Throup
tabling member	3960 label Biography information for Henry Smith

1459985

registered interest
date	25/04/2022
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Employment: Immunosuppression
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, whether Work Coaches are being given guidance on immunocompromised patients; and whether that guidance includes avoiding recommendations for in-person work for those individuals.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	158935
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>The Department is committed to providing the best possible support for all claimants to meet their individual circumstances. Claimants with a health condition or disability, including those who are immunocompromised, continue to have tailored commitments agreed based on their personal circumstances, including considering the impact of their health and wider situation.</p><p>Any work-related requirements are set in discussion with the claimant, tailored to their individual capability and circumstances, making them realistic and achievable. The guidance available to DWP staff outlines the easements which may be applied including that work search reflects the type and location of jobs which are appropriate to the individual.</p><p>Although DWP does not routinely provide guidance specifically on supporting people who are immunocompromised, we do ensure that staff are aware of the sources of information available to them relating to medical conditions that are associated with this. Staff are signposted to tools, guidance support and websites to effectively use resources from both internal and external sites, such as information directly from the NHS.</p><p>This ensures that staff can access the most up to date advice and can use this to inform how they support individual customers.</p> answering member constituency Mid Sussex answering member printed Mims Davies question first answered 28/04/2022 09:03:45 answering member 4513 label Biography information for Mims Davies
tabling member	3960 label Biography information for Henry Smith

1459869

registered interest
date	22/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cardiovascular Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of implementing a ten year plan to tackle cardiovascular disease, similar to the ten year plans for cancer and mental health in development.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	157563
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>No specific assessment has been made.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 28/04/2022 10:43:40 answering member 4492 label Biography information for Maria Caulfield
tabling member	3960 label Biography information for Henry Smith

1459870

registered interest
date	22/04/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cardiovascular Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has for cardiovascular disease, including heart valve disease, to remain a priority in the updated NHS Long Term Plan.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	157562
answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>The National Health Service will continue to ensure cardiovascular disease services remain a priority in the updated NHS Long Term Plan, including diagnostic and treatment services for patients with heart failure and heart valve disease. The NHS is investing in cardiac networks to support whole pathway improvements, from prevention, diagnosis, treatment through to end of life care.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 28/04/2022 10:45:46 answering member 4492 label Biography information for Maria Caulfield
tabling member	3960 label Biography information for Henry Smith